Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?

Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias

(2021) Erica Howard et al.   NEUROLOGY

Predictors of cognitive impairment in Parkinson’s disease: a systematic review and meta-analysis of prospective cohort studies

(2020) Yu Guo et al.   JOURNAL OF NEUROLOGY

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

(2020) Gerald Novak et al.   Alzheimers Research & Therapy

ADNC-RS, a clinical-genetic risk score, predicts Alzheimer’s pathology in autopsy-confirmed Parkinson’s disease and Dementia with Lewy bodies

(2020) David L. Dai et al.   ACTA NEUROPATHOLOGICA

α-Synuclein modulates tau spreading in mouse brains

(2020) Fares Bassil et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

(2019) Lutz Frölich et al.   Alzheimers Research & Therapy

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies

(2019) Callum Smith et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Blood NfL

(2019) Chin-Hsien Lin et al.   NEUROLOGY

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

(2018) John L Robinson et al.   BRAIN

The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?

(2018) Xu Yan et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting

(2018) Rosebud O. Roberts et al.   JAMA Neurology

Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson’s Disease: The PPMI Dataset

(2018) Eleonora Fiorenzato et al.   JOURNAL OF ALZHEIMERS DISEASE

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

(2018) Maarten Timmers et al.   Alzheimers Research & Therapy

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders

(2018) David G. Coughlin et al.   ANNALS OF NEUROLOGY

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders

(2018) Bob Olsson et al.   JAMA Neurology

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

(2017) David J Irwin et al.   LANCET NEUROLOGY

APOE , thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease

(2017) Thomas F. Tropea et al.   MOVEMENT DISORDERS

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease

(2017) Cynthia M. Carlsson et al.   JOURNAL OF ALZHEIMERS DISEASE

Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies

(2016) A W Lemstra et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

(2016) Sara Hall et al.   MOVEMENT DISORDERS

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Synucleinopathies: past, present and future

(2016) M. G. Spillantini et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies

(2016) Guerry M. Peavy et al.   PARKINSONISM & RELATED DISORDERS

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

(2016) Henrik Zetterberg et al.   JAMA Neurology

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

(2015) Ju-Hee Kang et al.   Alzheimers & Dementia

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

(2015) Michael W. Weiner et al.   Alzheimers & Dementia

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease

(2015) Mark Terrelonge et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review

(2015) Myria Petrou et al.   MOVEMENT DISORDERS

MDS clinical diagnostic criteria for Parkinson's disease

(2015) Ronald B. Postuma et al.   MOVEMENT DISORDERS

Alpha-synuclein and tau: teammates in neurodegeneration?

(2014) Simon Moussaud et al.   Molecular Neurodegeneration

Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases

(2014) Jing L Guo et al.   NATURE MEDICINE

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Quality of life, health status and caregiver burden in Parkinson's disease: relationship to executive functioning

(2013) Aleksandra Kudlicka et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Confluence of α-Synuclein, Tau, and β-Amyloid Pathologies in Dementia With Lewy Bodies

(2013) Martí Colom-Cadena et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

(2011) Thomas J. Montine et al.   ACTA NEUROPATHOLOGICA

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial

(2011) Jeannie-Marie S. Leoutsakos et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

The economic impact of cognitive impairment in Parkinson's disease

(2011) Corinna Vossius et al.   MOVEMENT DISORDERS

The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease

(2011) Pablo Martinez-Martin et al.   MOVEMENT DISORDERS

MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI

(2011) Irene Litvan et al.   MOVEMENT DISORDERS

Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers

(2010) Alberto Serrano-Pozo et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

CSF biomarkers predict a more malignant outcome in Alzheimer disease

(2010) A. K. Wallin et al.   NEUROLOGY

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years

(2008) Mariese A. Hely et al.   MOVEMENT DISORDERS